|
1
|
Claerhout S, Lim JY, Choi W, et al: Gene
expression signature analysis identifies vorinostat as a candidate
therapy for gastric cancer. PLOS One. 6:e246622011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gong Y, Guo MZ, Ye ZJ, Zhang XL, Zhao YL
and Yang YS: Silence of HIN-1 expression through methylation of its
gene promoter in gastric cancer. World J Gastroenterol. 17:526–533.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Le XF, Mao W, Lu C, Thornton A, Heymach
JV, Sood AK and Bast RC Jr: Specific blockade of VEGF and HER2
pathways results in greater growth inhibition of breast cancer
xenografts that overexpress HER2. Cell Cycle. 7:3747–3758. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanson J, Gorman J, Reese J and Fraizer G:
Regulation of vascular endothelial growth factor, VEGF gene
promoter by the tumor suppressor, WT1. Front Biosci. 12:2279–2290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bachelder RE, Crago A, Chung J, Wendt MA,
Shaw LM, Robinson G and Mercurio AM: Vascular endothelial growth
factor is an autocrine survival factor for neuropilin-expressing
breast carcinoma cells. Cancer Res. 61:5736–5740. 2001.PubMed/NCBI
|
|
6
|
Matsuura M, Onimaru M, Yonemitsu Y, et al:
Autocrine loop between vascular endothelial growth factor (VEGF)-C
and VEGF receptor-3 positively regulates tumor-associated
lymphangiogenesis in oral squamoid cancer cells. Am J Pathol.
175:1709–1721. 2009. View Article : Google Scholar
|
|
7
|
Rinderknecht M, Villa A, Ballmer-Hofer K,
Neri D and Detmar M: Phage-derived fully human monoclonal antibody
fragments to human vascular endothelial growth factor-c block its
interaction with VEGF receptor-2 and 3. PLoS One. 5:e119412010.
View Article : Google Scholar
|
|
8
|
Lassoued W, Murphy D, Tsai J, Oueslati R,
Thurston G and Lee WM: Effect of VEGF and VEGF trap on vascular
endothelial cell signaling in tumors. Cancer Biol Ther.
10:1326–1333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng LF, Li YJ, Wang H, Zhao JL, Wang XF
and Hu YS: Combination of vascular endothelial growth factor
antisense oligonucleotied therapy and radiotherapy increases the
curative effects against maxillofacial VX2 tumors in rabbits. Eur J
Radio. 78:272–276. 2011. View Article : Google Scholar
|
|
10
|
Yin YM, Yu H, Zhou YB, Zhang WQ and Lv R:
Effects of lentivirus-mediated RNA interference on VEGF expression
in human gastric cancer cells. Shandong Med J. 49:51–53. 2009.(In
Chinese).
|
|
11
|
Menendez D, Krysiak O, Inga A, Krysiak B,
Resnick MA and Schonfelder G: A SNP in the flt-1 promoter
integrates the VEGF system into the p53 transcriptional network.
Proc Natl Acad Sci USA. 103:1406–1411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoeben A, Landuyt B, Highley MS, Wildiers
H, Oosterom AT and Bruijn EA: Vascular endothelial growth factor
and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Lu Z, Wientjes MG and Au JL:
Delivery of siRNA therapeutics: barriers and carriers. AAPS J.
12:492–503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo P, Coban O, Snead N, Trebley J,
Hoeprich S, Guo S and Shu Y: Engineering RNA for targeted siRNA
delivery and medical application. Adv Drug Deliv Rev. 62:650–666.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guan HT, Xue XH, Dai ZJ, Wang XJ, Li A and
Qin ZY: Down-regulation of survivin expression by small interfering
RNA induces pancreatic cancer cell apoptosis and enhances its
radiosensitivity. World J Gastroenterol. 12:2901–2907.
2006.PubMed/NCBI
|
|
16
|
Yao L, Liu F, Hong L, Sun L, Liang S, Wu K
and Fan DM: The function and mechanism of COX-2 in angiogenesis of
gastric cancer cells. J Exp Clin Cancer Res. 30:132011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun P, Gao J, Liu YL, Wei LW, Wu LP and
Liu ZY: RNA interference (RNAi)-mediated vascular endothelial
growth factor-C (VEGF-C) reduction interferes with
lymphangiogenesis and enhances epirubicin sensitivity of breast
cancer cells. Mol Cell Biochem. 308:161–168. 2008. View Article : Google Scholar
|
|
18
|
Kim SH, Lee SH, Tian H, Chen X and Park
TG: Prostate cancer cell-specific VEGF siRNA delivery system using
cell targeting peptide conjugated polyplexes. J Drug Target.
17:311–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasan MR, Ho SH, Owen DA and Tai IT:
Inhibition of VEGF induces cellular senescence in colorectal cancer
cells. Int J Cancer. 129:2115–2123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raskopf E, Vogt A, Sauerbruch T and
Schmitz V: siRNA targeting VEGF inhibits hepatocellular carcinoma
growth and tumor angiogenesis in vivo. J Hepatol. 49:977–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun P, Yu H, Zhang WQ, Liu Y and Lv R:
Mechanism of the apoptosis of human gastric cancer cell line SUN
SGC7901 induced by vascular endothelial growth factor siRNA. J Med
Postgrad. 24:350–353. 2011.(In Chinese).
|
|
22
|
Bredow S, Juri DE, Cardon K and Tesfaigzi
Y: Identification of a novel Bcl-2 promoter region that counteracts
in a p53-dependent manner the inhibitory p2 region. Gene.
404:110–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guha M and Altieri DC: Survivin as a
global target of intrinsic tumor suppression networks. Cell Cycle.
8:2708–2710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng CX: SIRT1, is it a tumor promoter or
tumor suppressor? Int J Biol Sci. 5:147–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamakuchi M and Lowenstein CJ: MiR-34,
SIRT1 and p53: the feedback loop. Cell Cycle. 8:712–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung HB and Ahmad N: Role of p53 in the
anti-proliferative effects of Sirt1 inhibition in prostate cancer
cells. Cell Cycle. 8:1478–1483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han MK, Song EK, Gou Y, Ou X, Mantel C and
Broxmeyer HE: SIRT1 regulates apoptosis and Nanog expression in
mouse embryonic stem cells by controlling p53 subcellular
localization. Cell Stem Cell. 2:241–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
